VITA 34 Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Jakub Baran

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	2.5yrs
Participación del CEO	n/a
Permanencia media de la dirección	2.5yrs
Promedio de permanencia en la Junta Directiva	4.2yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Jakub Baran

2.5yrs

Permanencia

Mr. Jakub Julian Baran serves as Chairman of the Management Board and Chief Executive Officer at VITA 34 AG since March 22, 2022. He serves as Member of the Supervisory Board at Betacom S.A. since May 2019...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Jakub Baran	Chairman of the Management Board & CEO	2.5yrs	sin datos	sin datos
Tomasz Baran	Vice President of the Management Board & Chief Commercial Officer	2.5yrs	sin datos	sin datos
Thomas Pfaadt	Chief Financial Officer	less than a year	sin datos	sin datos
Santiago Luengo	Managing Director of Secuvita	no data	sin datos	sin datos

2.5yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de V3V se considera experimentado (2.5 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Isadore Ances	Member of Scientific & Medical Advisory Board	no data	sin datos	sin datos
A. Bader	Member of Scientific & Medical Advisory Board	no data	sin datos	sin datos
Robert Iannone	Member of Scientific & Medical Advisory Board	no data	sin datos	sin datos
W. Holzgreve	Member of Scientific & Medical Advisory Board	no data	sin datos	sin datos
Carlo Croce	Member of Scientific & Medical Advisory Board	no data	sin datos	sin datos
Jack Goldberg	Member of Scientific & Medical Advisory Board	no data	sin datos	sin datos
E. Wunder	Member of Scientific & Medical Advisory Board	no data	sin datos	sin datos
Ronald Wapner	Member of Scientific & Medical Advisory Board	no data	sin datos	sin datos
Zbigniew Mrowiec	Member of Scientific & Medical Advisory Board	no data	sin datos	sin datos
Florian Schuhbauer	Deputy Chairman of the Supervisory Board	4.2yrs	€20.00k	sin datos
Alexander Granderath	Chairman of Supervisory Board	2.8yrs	sin datos	sin datos
Frank Kohler	Independent Member of the Supervisory Board	7.3yrs	€30.00k	sin datos

4.2yrs

Permanencia media

Junta con experiencia: La junta directiva de V3V se considera experimentada (3.9 años de antigüedad promedio).

VITA 34 Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

VITA 34 AG, Annual General Meeting, Jun 29, 2022

VITA 34 AG, Annual General Meeting, Jun 30, 2021

Recent updates

Second quarter 2024 earnings released: €0.10 loss per share (vs €0.07 loss in 2Q 2023)

First quarter 2024 earnings released: €0.05 loss per share (vs €0.18 loss in 1Q 2023)

New major risk - Revenue and earnings growth

Price target increased by 15% to €6.00

No longer forecast to breakeven

VITA 34 AG to Report Q1, 2024 Results on May 31, 2024

New minor risk - Share price stability

New minor risk - Profitability

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: €0.10 loss per share (vs €0.02 loss in 3Q 2022)

Second quarter 2023 earnings released: €0.07 loss per share (vs €0.30 loss in 2Q 2022)

New minor risk - Share price stability

New minor risk - Market cap size

First quarter 2023 earnings released: €0.18 loss per share (vs €0.18 loss in 1Q 2022)

Vita 34 Ag Starts Recruitment for Clinical Trial with Car-T Drug Candidate

Full year 2022 earnings released: €1.71 loss per share (vs €0.63 loss in FY 2021)

VITA 34 AG to Report Q3, 2023 Results on Nov 21, 2023

Third quarter 2022 earnings released: €0.02 loss per share (vs €0.11 profit in 3Q 2021)

Price target decreased to €10.50

Second quarter 2022 earnings released: EPS: €0.30 (vs €0.002 loss in 2Q 2021)

VITA 34 AG Revises Earnings Guidance for the Financial Year 2022

VITA 34 AG to Report Q2, 2022 Results on Aug 30, 2022

VITA 34 AG, Annual General Meeting, Jun 29, 2022

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

VITA 34 AG to Report Q1, 2022 Results on May 31, 2022

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Vita 34 Ag Provides Revenue Guidance for the Financial Year 2022

Price target increased to €25.00

Price target increased to €21.10

Third quarter 2021 earnings released: EPS €0.14 (vs €0.18 in 3Q 2020)

Second quarter 2021 earnings released

VITA 34 AG (XTRA:V3V) entered into a Business Combination Agreement to acquire Polski Bank Komórek Macierzystych S.A. (WSE:BKM) (PKBM) from AOC Health GmbH, Jakub Baran, Tomasz Baran and others for approximately PLN 840 million.

VITA 34 AG Provides Earnings Guidance for the Year 2021

First quarter 2021 earnings released

Full year 2020 earnings released: EPS €0.37 (vs €0.18 in FY 2019)

VITA 34 AG to Report Q1, 2021 Results on May 11, 2021

New 90-day high: €14.05

New 90-day high: €13.00

VITA 34 AG, Annual General Meeting, Jun 30, 2021

Price target raised to €17.50

Third quarter 2020 earnings released: EPS €0.18

Revenue and earnings miss expectations

New 90-day low: €11.15

Earnings released

VITA 34 AG to Report Q2, 2020 Results on Aug 27, 2020

New 90-day low - €11.60

AOC Health GmbH acquired a 27.3% stake in VITA 34 AG (XTRA:V3V).

CEO

Permanencia

Equipo directivo

Permanencia media

Miembros de la Junta

Permanencia media